Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share rose 12 ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The stock's fall snapped a four-day winning streak.

The stock exceeded the S&P 500 ... The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its ...

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories ( ABT -1.00%), AbbVie ( ABBV 2.86%), ...

In this note, we discuss Pfizer’s stock performance, key takeaways from its recent results, and valuation. PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around ...

Below is some historical data on the post-earnings performance of Pfizer stock compared to the stock performance of peers that reported their earnings just before Pfizer. For a fair comparison ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...